Biodesix INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BDSX
Biodesix INCBiodesix, Inc. announced a 24% increase in total revenue for fiscal year 2025, reaching $88.5 million, driven by growth in lung diagnostic testing and development services, while also extending its senior secured term loan maturity to November 2028.
NASDAQ
BDSX
Biodesix INCBiodesix, Inc. (BDSX) announced a 45% year-over-year increase in total revenue for 2024, reaching $71.3 million, fueled by strong growth in both Lung Diagnostic Testing and Development Services.
NASDAQ
BDSX
Biodesix INC10-K: Biodesix Secures Loan Waiver Amidst Financial Challenges, Reports 28% Revenue Increase in 2023
Biodesix obtains a limited waiver from lenders regarding financial reporting and revenue targets, while reporting a 28% increase in total revenue for 2023, driven by a 54% surge in lung diagnostic revenue.